Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q4 EPS by 46c, provides product guidance

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q4 EPS of $0.35, $0.46 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $83.4 million versus the consensus estimate of $72.36 million.

Financial Guidance:

Kiniksa expects 2024 ARCALYST net product revenue of between $360 million and $380 million.
Kiniksa expects that its cash, cash equivalents, and short-term investments will fund its current operating plan into at least 2027.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating